Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Bruna

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Neural Regeneration Research|June 5, 2018
Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathyJordi Bruna, Roser Velasco
Lung Cancer (Amsterdam, Netherlands)|December 25, 2025
Tarlatamab in routine clinical care: How much safety is enough?Ernest Nadal, Jordi Bruna
Toxics|October 24, 2017
Taxane-Induced Peripheral NeurotoxicityRoser Velasco, Jordi Bruna
Continuum (Minneapolis, Minn.)|April 4, 2015
Patient management problemJordi Bruna, Patrick Y Wen
Continuum (Minneapolis, Minn.)|April 4, 2015
Patient management problem-preferred responsesJordi Bruna, Patrick Y Wen
Current Treatment Options in Neurology|June 28, 2012
Leptomeningeal metastasesJordi Bruna, Marta Simó, Roser Velasco
Expert Review of Clinical Pharmacology|May 10, 2013
Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatmentJordi Bruna, Júlia Miró, Roser Velasco
JAMA Oncology|July 31, 2025
Concerns About Conclusions of the POLAR TrialLise Ventzel, Jordi Bruna, Guido Cavaletti
Aging|July 15, 2021
Senescence in neurons: an open issueJordi Bruna, Aina Calls, Victor J Yuste
Neuro-Oncology Advances|September 22, 2025
Reaching the point-of-no-return: The cornerstone of glioblastoma treatment?Montse Alemany, Jordi Bruna, Victor J Yuste
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Neural Regeneration Research|June 5, 2018
Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathyJordi Bruna, Roser Velasco
Lung Cancer (Amsterdam, Netherlands)|December 25, 2025
Tarlatamab in routine clinical care: How much safety is enough?Ernest Nadal, Jordi Bruna
Toxics|October 24, 2017
Taxane-Induced Peripheral NeurotoxicityRoser Velasco, Jordi Bruna
Continuum (Minneapolis, Minn.)|April 4, 2015
Patient management problemJordi Bruna, Patrick Y Wen
Continuum (Minneapolis, Minn.)|April 4, 2015
Patient management problem-preferred responsesJordi Bruna, Patrick Y Wen
Current Treatment Options in Neurology|June 28, 2012
Leptomeningeal metastasesJordi Bruna, Marta Simó, Roser Velasco
Expert Review of Clinical Pharmacology|May 10, 2013
Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatmentJordi Bruna, Júlia Miró, Roser Velasco
JAMA Oncology|July 31, 2025
Concerns About Conclusions of the POLAR TrialLise Ventzel, Jordi Bruna, Guido Cavaletti
Aging|July 15, 2021
Senescence in neurons: an open issueJordi Bruna, Aina Calls, Victor J Yuste
Neuro-Oncology Advances|September 22, 2025
Reaching the point-of-no-return: The cornerstone of glioblastoma treatment?Montse Alemany, Jordi Bruna, Victor J Yuste
Pageof 14